Company Overview
About Aignostics
Aignostics is a Berlin-based precision pathology company founded in 2019 as a spinout from Charité – Universitätsmedizin Berlin, one of Europe''s largest university hospitals. The company develops foundation models and AI-powered image analysis tools for computational pathology — applying deep learning to digitized histopathology slides (whole slide images) to detect, classify, and quantify cellular and tissue features at scale. Its technology enables pharmaceutical companies, contract research organizations (CROs), and diagnostic laboratories to analyze tissue samples faster, more consistently, and with greater quantitative depth than human pathologists alone.
Business Model & Competitive Advantage
Aignostics raised over €45M in total funding, including a €37M Series B in 2024 led by Balderton Capital with participation from Redalpine, Heartcore, Wilbe, and others. Strategic partnerships include AstraZeneca, Bayer, and Charité Berlin, positioning Aignostics at the interface of clinical research, drug development, and diagnostic innovation. The company''s AI models are trained on large-scale, curated pathology datasets and are designed to support both exploratory biomarker discovery in early-phase drug trials and regulatory-grade analysis in clinical diagnostics.
Competitive Landscape 2025–2026
Aignostics'' foundation model approach — building large, general-purpose pathology AI models that can be fine-tuned for specific indications — differentiates it from earlier, narrowly trained diagnostic AI tools. This positions the company alongside global leaders in computational pathology such as Paige.AI and PathAI, with a distinct European clinical data advantage through its Charité partnership. As digital pathology adoption accelerates driven by whole slide imaging infrastructure investment, Aignostics is positioned to serve as a core AI intelligence layer for both pharmaceutical R&D and next-generation clinical diagnostic workflows.
Key Differentiators
Emerging Innovator
Aignostics is an emerging player bringing innovative solutions to the Life Sciences & BioTech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
ConcertAI
ConcertAI is a Boston-based company that combines artificial intelligence with real-world oncology data to accelerate cancer drug development and improve patient outcomes. Its platform integrates mult
DNAnexus
DNAnexus is the category-defining cloud platform for precision health data management, analysis, and collaboration. Founded in 2009 and headquartered in Mountain View, California, DNAnexus provides a
Tempus
Tempus AI is a technology company applying artificial intelligence to advance precision medicine across oncology, neurology, psychiatry, and cardiology. Founded in 2015 by Eric Lefkofsky (co-founder o
Schrödinger
Schrödinger was founded in 1990 by Richard Friesner and David Pearlman in New York City, building physics-based computational methods for molecular simulation. For over 30 years the company has develo
Emulate
Emulate, Inc. is a Boston-based biotechnology company that designs, manufactures, and commercializes Organ-Chip technology — micro-engineered devices lined with living human cells that replicate the m
Florence Healthcare
Florence Healthcare is the dominant software platform for clinical trial site enablement, providing digital tools that connect trial sites, sponsors, and contract research organizations (CROs) to stre
Compare Aignostics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Aignostics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Aignostics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Aignostics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →